Delving into the Latest Updates on JT Pharmaceuticals with Synapse

概览

疾病领域	数量

神经系统疾病	3

排名前五的药物类型	数量

小分子化药	3

排名前五的靶点	数量

NTSR1(神经降压素受体1)	2
κ opioid receptor(κ-阿片受体)	1

关联

4

项与 JT Pharmaceuticals 相关的药物

TP-2021

靶点

κ opioid receptor

作用机制

κ opioid receptor激动剂

在研机构

Medical University of South Carolina [+2]

原研机构

JT Pharmaceuticals

在研适应症

瘙痒 [+1]

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

HPI-363

靶点

NTSR1

作用机制

NTSR1激动剂

在研机构

JT Pharmaceuticals [+1]

原研机构

Emory University

在研适应症

行为障碍 [+3]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

HPI-201

靶点

NTSR1

作用机制

NTSR1激动剂

在研机构

JT Pharmaceuticals

原研机构

Halimed Pharmaceuticals Inc.

在研适应症

神经痛

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期-

100 项与 JT Pharmaceuticals 相关的临床结果

登录后查看更多信息

0 项与 JT Pharmaceuticals 相关的专利（医药）

登录后查看更多信息

2

项与 JT Pharmaceuticals 相关的文献（医药）

2016-07-01·Stroke1区 · 医学

Improved Therapeutic Benefits by Combining Physical Cooling With Pharmacological Hypothermia After Severe Stroke in Rats

1区 · 医学

Article

作者: Lee, Jin Hwan ; Wei, Ling ; Yu, Shan Ping ; Wei, Zheng Zachory ; Won, Soonmi ; Dix, Thomas A. ; Gu, Xiaohuan

Background and Purpose—Therapeutic hypothermia is a promising strategy for treatment of acute stroke. Clinical translation of therapeutic hypothermia, however, has been hindered because of the lack of efficiency and adverse effects. We sought to enhance the clinical potential of therapeutic hypothermia by combining physical cooling (PC) with pharmacologically induced hypothermia after ischemic stroke.Methods—Wistar rats were subjected to 90-minute middle cerebral artery occlusion by insertion of an intraluminal filament. Mild-to-moderate hypothermia was induced 120 minutes after the onset of stroke by PC alone, a neurotensin receptor 1 (NTR1) agonist HPI-201 (formally ABS-201) alone or the combination of both. The outcomes of stroke were evaluated at 3 and 21 days after stroke.Results—PC or HPI-201 each showed hypothermic effect and neuroprotection in stroke rats. The combination of PC and HPI-201 exhibited synergistic effects in cooling process, reduced infarct formation, cell death, and blood-brain barrier damages and improved functional recovery after stroke. Importantly, coapplied HPI-201 completely inhibited PC-associated shivering and tachycardia.Conclusions—The centrally acting hypothermic drug HPI-201 greatly enhanced the efficiency and efficacy of conventional PC; this combined cooling therapy may facilitate clinical translation of hypothermic treatment for stroke.

Frontiers in Neuroscience3区 · 医学

Increased Brain Neurotensin and NTSR2 Lead to Weak Nociception in NTSR3/Sortilin Knockout Mice

3区 · 医学

ArticleOA

作者: Morales, Carlos R ; Deval, Emmanuel ; Devader, Christelle ; Roulot, Morgane ; Mazella, Jean ; Dix, Thomas ; Moreno, Sébastien

The neuropeptide neurotensin (NT) elicits numerous pharmacological effects through three different receptors (NTSR1, NTSR2, and NTSR3 also called sortilin). Pharmacological approaches and generation of NTSR1 and NTSR2-deficient mice allowed to determine the NT-induced antipsychotic like behavior, the inhibitory of weak fear memory and the nociceptive signaling in a rat formalin tonic pain model to NTSR1. Conversely, the effects of NT on thermal and tonic nociceptions were mediated by NTSR2. However, the role of NTSR3/sortilin on the neurotensinergic system was not investigated. Here, by using C57Bl/6J mouse model in which the gene coding for NTSR3/sortilin has been inactivated, we observed a modification of the expression of both NTSR2 and NT itself. Quantitative PCR and protein expression using Western blot analyses and AlphaLisa™ technology resulted in the observation that brain NTSR2 as well as brain and blood NT were 2-fold increased in KO mice leading to a resistance of these mice to thermal and chemical pain. These data confirm that NTSR3/sortilin interacts with other NT receptors (i.e., NTSR2) and that its deletion modifies also the affinity of this receptor to NT.

100 项与 JT Pharmaceuticals 相关的药物交易

登录后查看更多信息

100 项与 JT Pharmaceuticals 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

1

2

临床前

其他

1

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

HPI-363 ( NTSR1 )	创伤性脑损伤更多	临床前
TP-2021 ( κ opioid receptor )	疼痛更多	临床前
HPI-201 ( NTSR1 )	神经痛更多	药物发现
JT-201	神经痛更多	无进展